Loading...
•
Sep 30, 2021
Sotera Health Q3 2021 Earnings Report
Sotera Health's third-quarter results for 2021 showed revenue growth, driven by strong performance in Sterigenics and Nordion segments, while Nelson Labs experienced a slight revenue decrease due to reduced pandemic-related demand.
Key Takeaways
Sotera Health reported a 13.1% increase in net revenues to $226 million for the third quarter of 2021, compared to $200 million in the same period last year. Net income attributable to Sotera Health was $27 million, or $0.10 per diluted share, compared to net income of $0.01 million, or $0.00 per diluted share in the third quarter of 2020. Adjusted EBITDA increased by 16.1% to $117 million. The company is narrowing its full-year 2021 revenue growth outlook to 12%-14% and Adjusted EBITDA growth to 13%-14%.
Net revenues for Q3 2021 increased by 13% to $226 million compared to Q3 2020.
Net income for Q3 2021 was $27 million, or $0.10 per diluted share, compared to $0.01 million, or $0.00 per diluted share in Q3 2020.
Adjusted EBITDA for Q3 2021 increased by 16% to $117 million compared to Q3 2020.
Adjusted EPS for Q3 2021 was $0.21, an increase of $0.12 compared to Q3 2020.
Revenue by Segment
Forward Guidance
Sotera Health is updating its 2021 outlook and expects net revenues in the range of $920 million - $930 million, representing growth of 12% - 14%, and Adjusted EBITDA of $475 million - $480 million, representing growth of 13% - 14%. They anticipate an Adjusted EPS of $0.87 - $0.88.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...